Table 4.
Average resource use and costs during 1 year after randomization
| Resource use (units/patient) | Cost (€/patient) | ||||||
|---|---|---|---|---|---|---|---|
| CO-PCI | MV-PCI | Incremental | CO-PCI | MV-PCI | Incremental | p value | |
| Number of urgent/staged PCIs | 0.324 | 0.093 | 0.231 | 1052 | 302 | 751 | < 0.001 |
| Hospitalizations | |||||||
| ICU nights | 7.832 | 7.526 | 0.305 | 7522 | 7229 | 293 | 0.679 |
| Normal ward nights | 5.246 | 5.820 | − 0.574 | 1500 | 1664 | − 164 | 0.432 |
| Impatient days | 2.138 | 3.758 | − 1.620 | 611 | 1074 | − 463 | 0.243 |
| Emergency room visits | 0.381 | 0.259 | 0.122 | 149 | 101 | 48 | 0.486 |
| Number of renal rep. therapy | |||||||
| Continuous dialysis | 0.044 | 0.093 | − 0.049 | 35 | 75 | − 40 | 0.013 |
| Hemodiafiltration | 0.031 | 0.028 | 0.003 | 29 | 26 | 3 | 0.806 |
| Hemofiltration | 0.025 | 0.034 | − 0.009 | 24 | 33 | − 9 | 0.494 |
| Intermittent dialysis | 0.016 | 0.012 | 0.003 | 4 | 3 | 1 | 0.731 |
| Number renal failure long term | 0.019 | 0.028 | − 0.009 | 1211 | 1806 | − 594 | 0.441 |
| Stents | 2.688 | 3.582 | − 0.894 | 185 | 246 | − 61 | < 0.001 |
| Angiography (minutes in fluoroscopy) | 18.353 | 22.540 | − 4.187 | 426 | 523 | − 97 | < 0.001 |
| Number of ICDs | 0.040 | 0.043 | − 0.003 | 113 | 121 | − 8 | 0.857 |
| Number of ECMOs | 0.062 | 0.102 | − 0.040 | 600 | 984 | − 384 | 0.066 |
| Number of IABPs | 0.090 | 0.080 | 0.010 | 115 | 102 | 12 | 0.655 |
| Number of LVADs | 0.140 | 0.118 | 0.023 | 6046 | 5074 | 972 | 0.407 |
| Number of heart transplants | 0.003 | 0.000 | 0.003 | 62 | 0 | 62 | 0.316 |
| Number of investigations procedures | |||||||
| Scintigraphy | 0.003 | 0.000 | 0.003 | 0 | 0 | 0 | 0.316 |
| Stress-echocardiogram | 0.000 | 0.015 | − 0.015 | 0 | 0 | 0 | 0.025 |
| MRI | 0.006 | 0.000 | 0.006 | 2 | 0 | 2 | 0.156 |
| Days of medications | |||||||
| Aspirin | 12.545 | 13.250 | − 0.706 | 0 | 0 | − 0 | 0.570 |
| Clopidogrel | 6.274 | 6.666 | − 0.392 | 70 | 74 | − 4 | 0.720 |
| Prasugrel | 3.625 | 4.114 | − 0.490 | 5 | 6 | − 1 | 0.531 |
| Ticagrelor | 4.777 | 4.455 | 0.322 | 7 | 6 | 0 | 0.692 |
| Vitamin-K-antagonists | 1.628 | 1.407 | 0.221 | 3 | 3 | 0 | 0.687 |
| GP IIb/IIIa-inhibitors | 0.224 | 0.220 | 0.004 | 42 | 41 | 1 | 0.891 |
| UF heparin | 10.439 | 10.524 | − 0.085 | 0 | 0 | − 0 | 0.942 |
| LMW heparin | 1.620 | 2.584 | − 0.964 | 25 | 39 | − 15 | 0.118 |
| Bivalirudin | 0.050 | 0.068 | − 0.018 | 25 | 34 | − 9 | 0.326 |
| Fondaparinux | 0.380 | 0.573 | − 0.193 | 0 | 1 | − 0 | 0.566 |
| Beta-blocker | 10.465 | 10.035 | 0.430 | 94 | 90 | 4 | 0.713 |
| ACE-inhibitor/AT-II-antagonist | 9.503 | 8.743 | 0.760 | 14 | 13 | 1 | 0.499 |
| Statins | 11.095 | 11.043 | 0.052 | 43 | 43 | 0 | 0.965 |
| Calcium-antagonist | 1.734 | 1.308 | 0.426 | 0 | 0 | 0 | 0.416 |
| Aldosterone-antagonist | 3.690 | 4.082 | − 0.392 | 4 | 5 | − 0 | 0.664 |
| Diuretics | 9.042 | 8.048 | 0.994 | 0 | 0 | 0 | 0.376 |
| Edoxaban | 0.022 | 0.000 | 0.022 | 0 | 0 | 0 | 0.316 |
| Apixaban | 0.257 | 0.310 | − 0.053 | 1 | 1 | − 0 | 0.811 |
| Rivaroxaban | 0.595 | 0.121 | 0.474 | 1 | 0 | 1 | 0.035 |
| Dabigatran | 0.204 | 0.337 | − 0.133 | 0 | 0 | − 0 | 0.596 |
| Catecholamine therapy | 6.406 | 6.657 | − 0.251 | 6 | 7 | − 0 | 0.133 |
| Work hours lost | 154.642 | 139.022 | 15.620 | 5343 | 4803 | 540 | 0.365 |
| Total | 25,371 | 24,531 | 841 | 0.679 | |||
| N | 321 | 323 | 321 | 323 | |||
Medication are expressed in days receiving the standard dose, except for the case of GP IIb/IIIa-inhibitors, UF heparin, bivalirudin and catecholamine therapy, where proportion of patient receiving medication is shown